HAEMONETICS CORP — Director's Dealing 2021

Feb 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2021-02-04

Reporting Person: MEELIA RICHARD J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-04	Common Stock	M	10353	$35.5025	Acquired	42403	Direct
2021-02-04	Common Stock	S	10353	$134.64	Disposed	32050	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-04	Non-qualified Stock Option (Right to Buy)	$35.5025	M	10353	Disposed	2021-07-23	Common Stock (10353)	Direct

Footnotes

F1: The reporting person exercised options that were granted in 2014 and scheduled to expire on July 23, 2021, as reflected in this Form 4.

F2: This number includes unvested restricted stock units previously reported.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.39 to $135.30, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: Options vest 100% on the first anniversary of the date of grant.